We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

Written answer

Medicinal Products

872. Deputy James Geoghegan asked the Minister for Health to review matters raised in correspondence (details supplied). [78963/26]

Comment on this

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices.

The HSE has advised that it is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it.

The HSE must robustly assess applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.

There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed. HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.

In terms of the specific details of the application for pricing and reimbursement of Acarizax®

The HSE received an application for pricing / reimbursement on the 10th December 2025 from ALK-Abello (the applicant) for Acarizax indicated in patients (5-65 years) diagnosed by clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE), with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.

The first step in the process is the submission of a Rapid Review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The HSE commissioned the Rapid Review process on the 9th December 2025.

The NCPE Rapid Review assessment report was received by the HSE on the 22nd December 2025. The NCPE advised the HSE that a full Health Technology Assessment (HTA) a full HTA is recommended to assess the clinical effectiveness and cost effectiveness of 12 SQ-HDM for this indication compared with the current standard of care.

The HSE commissioned a full HTA on the 28th January 2026 as per agreed processes and the HSE advise that this HTA is ongoing.  Details on the NCPE assessment may be viewed online at: www.ncpe.ie/house-dust-mite-extract-acarizax-for-allergic-rhinitis-5-65-year-olds-hta-id-25069

The HSE must await the recommendation arising from the established assessment process before considering any subsequent steps. Updates on the progress of Acarizax through the HSE assessment and approval processes is available via the Pricing and Reimbursement Application tracker HSE - PCRS.

Comment on this